Introduction
Thiamine, in its biologically active form of thiamine pyrophosphate, is an essential coenzyme for oxidative cellular metabolism (Sechi et al. Reference Sechi, Sechi and Fois2016a). However, as humans cannot synthesize thiamine in the body, they rely on external sources. Moreover, the physiological stores are small, and thiamine deficiency (TD) may occur if a loss of appetite continues for 2–3 weeks (Sechi et al. Reference Sechi, Sechi and Fois2016a). Wernicke encephalopathy (WE) is well known as a serious disease caused by TD. If left untreated, Korsakoff syndrome may develop, resulting in irreversible brain damage (Sechi and Serra Reference Sechi and Serra2007). The treatment of TD is preferably the parenteral administration of thiamine, and early detection and treatment allows the disease to be resolved without sequelae. However, the neuropsychiatric symptoms exhibited by TD patients are nonspecific, and cases in which the symptoms are mild or vague often go undiagnosed (Fozi et al. Reference Fozi, Azmi and Kamariah2006; Harper et al. Reference Harper, Giles and Finlay-Jones1986; Onishi et al. Reference Onishi, Ishida and Uchida2019b). At present, the most useful diagnostic tool for TD is clinical suspicion (Sechi and Serra Reference Sechi and Serra2007). For this reason, it is essential that we increase our knowledge of the classical features of TD as well as of other possible, more uncommon symptoms.
Herein, we report a case of TD mimicking major depressive disorder (MDD) in which the patient showed severe mental symptoms including attempted suicide, depression, low motivation, and frustration.
Case report
A gynecological oncologist referred a 58-year-old female patient with endometrial cancer to the psycho-oncology department.
Three years earlier, the patient visited an emergency center due to massive genital bleeding. As a result of detailed examination in the gynecology department, she was suspected as Stage IA endometrial cancer and underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy. The patient was diagnosed with endometrial cancer, Stage IA (pT1aNXM0). She was followed up regularly by a gynecological oncologist.
Three months before her visit to our clinic, lung metastasis and pelvic dissemination were confirmed by computed tomography/magnetic resonance imaging, and recurrence was diagnosed.
Two months before her visit, at the start of the first course of docetaxel and carboplatin (DC) therapy, the patient’s physical findings were as follows: height, 153 cm; weight, 45 kg; and body mass index (BMI), 19.22 kg/m2.
A few days after the start of DC administration, the patient experienced a loss of appetite and vomiting (about 10 times a day) that persisted for about a week, but she gradually recovered. The second course of treatment was completed without any symptoms of loss of appetite or vomiting. Two weeks before her visit, during the third course of treatment, the patient experienced vomiting about 5 times a day from the day after administration, with marked loss of appetite and dysgeusia, and she took only 1 mouthful of fruit and ice cream a day for about a week, leading to increased fatigue.
Ten days before her visit, the patient experienced severe nausea and 15 mg of metoclopramide was additionally administered.
Seven days before her visit, she visited the gynecology department for a special examination. Her notebook, in which she recorded her physical symptoms and feelings, contained the following comments describing her anxiety regarding future treatment: “I have no place to put my feelings,” “I am causing trouble to everyone because of my weakness,” “I can’t enjoy the things I used to enjoy.” At her request, she was referred to the psycho-oncology department.
On her first visit to the psycho-oncology department, she appeared restless. During the examination, she couldn’t sit calmly and remained standing in the room while responding to inquiries. She stated that “I’m trembling,” “I have heart palpitations,” and “Today is the hardest” in quick succession. Then, while gesturing with her hands around her throat, she complained, “I choked myself with both hands.”
Further interviews were recommended, and a depressed mood and decreased motivation were observed. The patient’s appetite decreased to about 10% of normal, and she slept poorly, waking every hour and experiencing nightmares. The patient was observed to demonstrate signs of frustration, such as feeling trapped and restless, and she also complained of general malaise, difficulty in concentrating, and feelings of guilt. These symptoms caused her clinically significant distress.
Neurologically, bilateral tremors were present, but no ataxia, ocular symptoms, or decreased level of consciousness were noted. She had noted “dizziness” in the notebook and there were some irregularities in her writing.
Physically, she weighed 43 kg (BMI, 18.37 kg/m2), with a body temperature of 36.5°C, blood pressure of 114/80 mm Hg, pulse of 88 bpm, and oxygen saturation of 98%. No special features were observed in her blood and biochemical data (Table 1).
Abbreviations: AST-aspartate aminotransferase; ALT-alanine aminotransferase.
She had no history of depression or psychiatric illness, nor was there a history of alcohol or substance abuse. Personality-wise, she was earnest, warm-hearted, and deeply trusted by those around her.
The above mental and physical symptoms met the list of A items as symptoms of depression under the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th edition (American Psychiatric Association 2013). A 2-week period of decreased appetite is one of the diagnostic criteria for depression. However, this also corresponds to the period during which TD might develop (Sechi et al. Reference Sechi, Sechi and Fois2016a), so we also suspected TD and intravenously administered 200 mg of thiamine. When the patient was examined again after 1 hour, there was a significant change in symptoms, with the patient stating, “I feel better,’’ “I no longer have heart palpitations,’’ and “the feeling of wanting to die has disappeared.’’ Thereafter, her appetite improved rapidly and, after the examination, she ate a normal amount of food at a restaurant with her family and went home.
Oral administration of mirtazapine 15 mg and aripiprazole 3 mg before bedtime was started from that day. On the next day, she reported that, “I was able to sleep for nine hours,” “I no longer have dizziness, lightheadedness, or headaches,” and “I have a strong desire to undergo cancer treatment.” She also reported that she no longer experienced tremors. According to the patient, her appetite improved thereafter, and she ate hamburgers with her family even before examinations.
Four days later, her weight had increased by 2 kg, and she declared that, “I don’t want to die now. I want to live.” Her family also reported that she had increased her food intake.
Five days later, the patient’s serum thiamine concentration was found to be 14 ng/mL (reference range: 24–66 ng/mL), which was abnormally low (Table 2).
Based on the above, this patient was diagnosed with TD, and oral administration of thiamine 100 mg was continued. No recurrence of similar symptoms has since been observed.
Discussion
We experienced a case in whom depression was initially suspected as the cause of severe psychiatric symptoms including attempted suicide and frustration. However, in consideration of the possibility of TD, she was intravenously administered thiamine and her subjective mental symptoms almost disappeared before the start of treatment for depression.
The cause of TD in this case was understood to be a reduced appetite (Sechi et al. Reference Sechi, Sechi and Fois2016a), but the possibility of chemotherapy-induced TD cannot be ruled out (Sechi et al. Reference Sechi, Batzu and Agrò2016b).
When we tracked the time course of each psychiatric symptom in this case, suicidal ideation was observed to disappear on the day of thiamine administration at the outpatient clinic, and many symptoms such as loss of appetite also disappeared (Table 3). This is consistent with the report that TD is a risk factor for developing neuropsychiatric symptoms (Iimura et al. Reference Iimura, Kurokawa and Andoh2021).
Considering the symptoms and course, treatment for TD was the most urgent response, and it is thought that TD caused these symptoms mimicking MDD. Previous reports have also pointed out the relationship between decreased appetite due to depression and vitamin deficiency (Oudman et al. Reference Oudman, Wijnia and Oey2021), and caution should be exercised in differentiating comorbid depression and depressive states from TD.
The failure to consider the possibility of TD in cases like this, resulting in treatment with antidepressants alone, can lead to Korsakoff syndrome, an irreversible brain disorder.
At the examination, no disturbed consciousness was observed in this case. However, as delirium tends to show diurnal fluctuations, it is possible that her consciousness was disturbed at the time of her attempted suicide.
In addition, the administration of antidepressants was started even after symptoms improved in response to the administration of thiamine on an outpatient basis. As depression also shows diurnal fluctuations, it is possible that the symptoms of “suicidal ideation” were more marked at the time the suicide attempt was made. It is also possible for symptoms to become stronger again after examination; therefore, there is no leeway for a wait-and-see approach, and we believe that starting treatment with the prescription of antidepressants is important for life-threatening risk avoidance.
In conclusion, attempted suicide is a very serious action resulting from psychiatric symptoms. However, in oncological settings, as in this case, we should consider not only depression but also the possibility of TD as a physical disease. TD is a potentially iatrogenic condition and fatal if overlooked, but is reversible if detected early. Appropriate diagnosis and treatment, including early detection and differential diagnosis, are always important.
Acknowledgments
None.
Funding
This work was supported by JSPS KAKENHI Grant Number JP18K13327.
Competing interests
None.